Key Events This Week
7 Sep: Stock opens at Rs.1,639.90, Sensex down 0.46%
8 Sep: New 52-week high at Rs.1,850.95 and all-time high at Rs.1,777.50; Mojo Grade upgraded to Buy
9 Sep: Hits new 52-week and all-time high of Rs.2,067.50; surges 20% to Rs.2,186.40 hitting upper circuit
10 Sep: New 52-week and all-time high at Rs.2,394; ninth consecutive day of gains
11 Sep: Closes at Rs.2,393.15, slight dip of 1.32% amid profit-taking
7 September 2026: Modest Start Amid Market Weakness
Novartis India Ltd began the week at Rs.1,639.90, registering a modest gain of 0.17% despite the Sensex falling 0.46% to 36,218.97. Trading volume was robust at 145,528 shares, signalling early investor interest. The broader market’s weakness set a cautious tone, but the stock’s resilience hinted at underlying strength.
8 September 2026: Breakout with New 52-Week and All-Time Highs
On 8 September, Novartis India Ltd surged dramatically, hitting a new 52-week high of Rs.1,850.95 and an all-time high of Rs.1,777.50 during the session. The stock closed at Rs.1,823.35, up 11.19%, vastly outperforming the Sensex which declined 0.21%. This day marked the seventh consecutive session of gains, with a cumulative return of 24.49% over that period.
Technical indicators were strongly bullish, with the stock trading above all key moving averages. The MarketsMOJO Mojo Grade was upgraded from Hold to Buy on 8 September, reflecting improved technical and financial metrics. Delivery volumes surged, indicating heightened liquidity and investor conviction.
Financially, the company reported record quarterly net sales of Rs.103.81 crores and a profit after tax of Rs.32.21 crores for the latest quarter, signalling a turnaround after two subdued quarters. The net cash position stood at Rs.667.70 crores, underscoring strong liquidity.
9 September 2026: Momentum Accelerates with Upper Circuit Hit
Novartis India Ltd’s rally intensified on 9 September, hitting a new 52-week and all-time high of Rs.2,067.50 intraday and closing at Rs.2,186.40 after surging 20%, triggering the upper circuit limit. This represented an extraordinary single-day gain and extended the winning streak to eight consecutive sessions with a cumulative return of 37.81%.
The stock outperformed its Pharmaceuticals & Biotechnology sector by over 20% and the Sensex by nearly 22 percentage points. Intraday volatility was elevated, reflecting active trading and strong investor enthusiasm. The Mojo Score improved to 71.0, reinforcing the Buy rating.
Despite the sharp price appreciation, valuation multiples remained elevated, with a price-to-book ratio of 5.5 and a trailing P/E of 46 times, indicating premium pricing driven by growth expectations.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
10 September 2026: New Peak at Rs.2,394 and Ninth Consecutive Gain
Novartis India Ltd continued its impressive run on 10 September, reaching a new 52-week and all-time high of Rs.2,394. The stock closed near this peak after gaining 11.74% intraday, marking its ninth consecutive day of gains and a cumulative return of 58.26% over this period.
The stock outperformed the Pharmaceuticals & Biotechnology sector by 7.69% and the Sensex, which was marginally down 0.03%. Technical indicators remained strongly bullish, with the stock trading above all major moving averages. Intraday volatility was high at 385.5%, reflecting dynamic price action and active investor participation.
Financially, the company maintained its net-debt-free status and reported record quarterly operating profit before depreciation and interest of Rs.34.91 crores. Despite a 4.9% decline in profits over the past year, operating profit growth remained robust at an annualised 40.23%.
11 September 2026: Slight Profit-Taking Amid Strong Weekly Gains
On the final trading day of the week, 11 September, Novartis India Ltd closed at Rs.2,393.15, down 1.32% from the previous close. This minor pullback followed a week of extraordinary gains and is typical profit-taking behaviour after a sustained rally. The Sensex declined 0.39% on the day, continuing its broader downward trend.
Volume moderated to 42,326 shares, indicating a pause in the intense buying seen earlier in the week. The stock’s technical position remains strong, supported by the recent upgrade to a Buy rating and a Mojo Score of 71.0.
Curious about Novartis India Ltd from ? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Daily Price Comparison: Novartis India Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-07 | Rs.1,639.90 | +0.17% | 36,218.97 | -0.46% |
| 2026-09-08 | Rs.1,823.35 | +11.19% | 36,144.32 | -0.21% |
| 2026-09-09 | Rs.2,188.00 | +20.00% | 35,921.77 | -0.62% |
| 2026-09-10 | Rs.2,425.05 | +10.83% | 35,912.77 | -0.03% |
| 2026-09-11 | Rs.2,393.15 | -1.32% | 35,773.24 | -0.39% |
Key Takeaways from the Week
Strong Outperformance: Novartis India Ltd’s 46.18% weekly gain dwarfed the Sensex’s 1.68% decline, highlighting exceptional relative strength amid a challenging market.
Consistent Momentum: The stock recorded nine consecutive days of gains, reaching multiple new 52-week and all-time highs, signalling sustained investor confidence.
Financial Resilience: Robust quarterly results, a net-debt-free balance sheet, and record cash reserves underpin the stock’s rally despite a slight profit contraction over the past year.
Technical Strength: Trading above all key moving averages with bullish MACD and Bollinger Bands indicators, the stock’s technical profile supports continued momentum.
Valuation Premium: Elevated price-to-book and P/E ratios reflect high market expectations, warranting cautious monitoring of earnings trends and market sentiment.
Conclusion: A Week of Remarkable Gains Backed by Fundamentals and Technicals
Novartis India Ltd’s extraordinary 46.18% surge over the week ending 11 September 2026 stands out as a compelling market story. The stock’s ability to consistently outperform the Sensex and its sector peers amid a broadly weak market environment underscores its robust fundamentals and strong technical momentum. The upgrade to a Buy rating by MarketsMOJO and the sustained rally through multiple new highs reflect renewed investor confidence.
While valuation metrics remain elevated, the company’s strong cash position, operational improvements, and positive quarterly results provide a solid foundation. Investors should remain attentive to upcoming earnings releases and sector developments to assess the sustainability of this rally. Overall, Novartis India Ltd has demonstrated resilience and leadership within the Pharmaceuticals & Biotechnology sector, making it a noteworthy stock in the current market landscape.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
